Zobrazeno 1 - 10
of 501
pro vyhledávání: '"Mario E. Lacouture"'
Autor:
Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan F. Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin H. Kaffenberger, Bernice Y. Kwong, Timothy Pluard, Ruta Rao, Lee Schwartzberg, Michael S. Broder
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract Hyperglycemia and rash are expected but challenging adverse events of phosphatidylinositol-3-kinase inhibition (such as with alpelisib). Two modified Delphi panels were conducted to provide consensus recommendations for managing hyperglycemi
Externí odkaz:
https://doaj.org/article/8183fb8cce4340f9881e7c5f5b6eef4c
Autor:
Stephanie L. Gu, Tara Maier, Andrea P. Moy, Stephen Dusza, David M. Faleck, Neil J. Shah, Mario E. Lacouture
Publikováno v:
Pharmaceuticals, Vol 16, Iss 11, p 1548 (2023)
Background: Immune-related cutaneous adverse events (ircAEs) are frequent and may reduce quality of life and consistent dosing. IL12/23 has been implicated in psoriasis, which is reminiscent of the psoriasiform/lichenoid ircAE phenotype. We report th
Externí odkaz:
https://doaj.org/article/369a6933d8b2478d9b794bf01af6cc99
Autor:
Hope S. Rugo, Mario E. Lacouture, Marcus D. Goncalves, Umesh Masharani, Matti S. Aapro, Joyce A. O'Shaughnessy
Publikováno v:
Breast, Vol 61, Iss , Pp 156-167 (2022)
Purpose: The oral, α-specific phosphatidylinositol-3-kinase (PI3Kα) inhibitor alpelisib is the first PI3K inhibitor approved for the treatment of advanced breast cancer. As alpelisib is a relatively new therapeutic option, specific guidance and a m
Externí odkaz:
https://doaj.org/article/c6c4f39f76af47a99f7d292ece4d71d7
Autor:
Azael Freites-Martinez, Anastasia Navitski, Claire F. Friedman, Donald Chan, Shari Goldfarb, Mario E. Lacouture, Roisin E. O'Cearbhaill
Publikováno v:
Gynecologic Oncology Reports, Vol 44, Iss , Pp 101095- (2022)
Objective: To assess patient-perceived involvement in shared decision making among those diagnosed with breast or gynecologic malignancies undergoing chemotherapy associated with persistent chemotherapy-induced alopecia (pCIA). We also sought to iden
Externí odkaz:
https://doaj.org/article/e7b07c899fad4542bdf4c23548d67f40
Autor:
Brendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, Mario E. Lacouture, Soleen Ghafoor, Anthony M. Rossi, David N. Assis, Ying-Bei Chen, Klaus J. Busam, Yelena Y. Janjigian, Komal Jhaveri, Darren R. Feldman, Anne Capozzi, Vanessa Figueroa, Dean F. Bajorin, Jonathan E. Rosenberg, Travis J. Hollmann, Samuel A. Funt
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 1, Pp 430-438 (2021)
Metastatic primary cutaneous extramammary Paget disease (EMPD) is a rare clinical entity with a 5-year survival
Externí odkaz:
https://doaj.org/article/d76cb10bfe2348a4802b4d6e377656f7
Autor:
Siu-Fun Wong, Joseph M. Unger, James L. Wade, Lynne I. Wagner, Mario E. Lacouture, Keisha C. Humphries, Anna Moseley, Kathryn Arnold, Mario R. Velasco, Justin D. Floyd, Benjamin T. Esparaz, Afsaneh Barzi, Heinz-Josef Lenz, Marianna Koczywas, Shaker Dakhil, Gary V. Burton, Michael J. Fisch, N. Lynn Henry, Dawn L. Hershman, Carol M. Moinpour
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 4, Iss 1, Pp 1-12 (2020)
Abstract Background Papulopustular rash is a common class effect of epidermal growth factor receptor inhibitors (EGFRI) that can affect patients’ health-related quality of life and cause disruptions to treatment. SWOG S1013 (NCT01416688) is a multi
Externí odkaz:
https://doaj.org/article/cc8f4d5ab8574139b368be4cd9f29553
Autor:
Thomas J. Kaley, Katherine S. Panageas, Elena I. Pentsova, Ingo K. Mellinghoff, Craig Nolan, Igor Gavrilovic, Lisa M. DeAngelis, Lauren E. Abrey, Eric C. Holland, Antonio Omuro, Mario E. Lacouture, Emmy Ludwig, Andrew B. Lassman
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 7, Iss 4, Pp 429-436 (2020)
Abstract Purpose Malignant glioma (MG) is the most deadly primary brain cancer. Signaling though the PI3K/AKT/mTOR axis is activated in most MGs and therefore a potential therapeutic target. The mTOR inhibitor temsirolimus and the AKT inhibitor perif
Externí odkaz:
https://doaj.org/article/12a34fde3fdf4d90a2d5bd4a3dc14ad8
Autor:
Alyce M. Kuo, Lukas Kraehenbuehl, Stephanie King, Donald Y. M. Leung, Elena Goleva, Andrea P. Moy, Mario E. Lacouture, Neil J. Shah, David M. Faleck
Publikováno v:
Cancers, Vol 14, Iss 12, p 2995 (2022)
Immune-related adverse events (irAEs) frequently complicate treatment with immune checkpoint blockade (ICB) targeting CTLA-4, PD-1, and PD-L1, which are commonly used to treat solid and hematologic malignancies. The skin and gastrointestinal (GI) tra
Externí odkaz:
https://doaj.org/article/17f9e503c8e54c4d8e0f52e77e847f2c
Autor:
Mario E. Lacouture, Milan J. Anadkat, Matthew T. Ballo, Fabio Iwamoto, Suriya A. Jeyapalan, Renato V. La Rocca, Margaret Schwartz, Jennifer N. Serventi, Martin Glas
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Importance: Tumor Treating Fields (TTFields) are an anti-mitotic treatment approved for treating newly diagnosed and recurrent glioblastoma, and mesothelioma. TTFields in glioblastoma comprise alternating electric fields (200 kHz) delivered continuou
Externí odkaz:
https://doaj.org/article/1407100aef504fafbb08d1675907206e
Publikováno v:
International Journal of Women's Dermatology, Vol 6, Iss 3, Pp 220- (2020)
Externí odkaz:
https://doaj.org/article/46e21b39cf1447149f2430a296ab814b